Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.
2.

Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting.

Chen S, Qi X, Chen H, Li M, Gu J, Liu C, Xue H, Wang L, Geng Y, Qi P, Han Y.

Exp Ther Med. 2016 Jul;12(1):518-524. Epub 2016 Apr 20.

3.

Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.

Scott SA, Collet JP, Baber U, Yang Y, Peter I, Linderman M, Sload J, Qiao W, Kini AS, Sharma SK, Desnick RJ, Fuster V, Hajjar RJ, Montalescot G, Hulot JS.

Clin Pharmacol Ther. 2016 Sep;100(3):287-94. doi: 10.1002/cpt.401. Epub 2016 Jun 20.

PMID:
27213804
4.

Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia.

Zhu WY, Zhao T, Xiong XY, Li J, Wang L, Zhou Y, Gong ZL, Cheng SY, Liu Y, Shuai J, Yang QW.

Sci Rep. 2016 May 3;6:25478. doi: 10.1038/srep25478.

5.

Early dual antiplatelet therapy in stroke: should we take the CHANCE?

Brandler ES, Sharma M.

Ann Transl Med. 2015 Aug;3(13):177. doi: 10.3978/j.issn.2305-5839.2015.07.23. No abstract available.

6.

Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.

Lin G, Yi L, Zhang K, Wang L, Zhang R, Xie J, Li J.

PLoS One. 2015 Jul 28;10(7):e0134174. doi: 10.1371/journal.pone.0134174. eCollection 2015.

7.

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Yang Y, Lewis JP, Hulot JS, Scott SA.

Expert Opin Drug Metab Toxicol. 2015;11(10):1599-617. doi: 10.1517/17425255.2015.1068757. Epub 2015 Jul 14. Review.

8.

CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.

McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, Field TS, Talbert RL, Benavente OR, Johnson JA, Shuldiner AR.

J Am Heart Assoc. 2015 May 27;4(6):e001652. doi: 10.1161/JAHA.114.001652.

9.

Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.

Beitelshees AL, Voora D, Lewis JP.

Pharmgenomics Pers Med. 2015 Feb 9;8:43-61. doi: 10.2147/PGPM.S52900. eCollection 2015. Review.

10.

The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs.

Wakil SM, Nguyen C, Muiya NP, Andres E, Lykowska-Tarnowska A, Baz B, Tahir AI, Meyer BF, Morahan G, Dzimiri N.

Dis Markers. 2015;2015:542543. doi: 10.1155/2015/542543. Epub 2015 Feb 22.

11.

Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.

Zou JJ, Chen SL, Tan J, Lin L, Zhao YY, Xu HM, Lin S, Zhang J, Fan HW, Xie HG.

PLoS One. 2014 Jan 8;9(1):e84985. doi: 10.1371/journal.pone.0084985. eCollection 2014.

12.

Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.

Karaźniewicz-Łada M, Danielak D, Burchardt P, Kruszyna L, Komosa A, Lesiak M, Główka F.

Clin Pharmacokinet. 2014 Feb;53(2):155-64. doi: 10.1007/s40262-013-0105-2.

13.

Applied pharmacogenomics in cardiovascular medicine.

Weeke P, Roden DM.

Annu Rev Med. 2014;65:81-94. doi: 10.1146/annurev-med-101712-122545. Epub 2013 Oct 2. Review.

14.

The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects.

Kim HS, Kim GY, Yeo CW, Oh M, Ghim JL, Shon JH, Kim EY, Kim DH, Shin JG.

Br J Clin Pharmacol. 2014 May;77(5):821-30. doi: 10.1111/bcp.12236.

15.

Pharmacogenomics of anti-platelet and anti-coagulation therapy.

Fisch AS, Perry CG, Stephens SH, Horenstein RB, Shuldiner AR.

Curr Cardiol Rep. 2013 Jul;15(7):381. doi: 10.1007/s11886-013-0381-3. Review.

16.

Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?

Perry CG, Shuldiner AR.

J Hum Genet. 2013 Jun;58(6):339-45. doi: 10.1038/jhg.2013.41. Epub 2013 May 23. Review.

17.

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Johnson JA, Cavallari LH.

Pharmacol Rev. 2013 May 17;65(3):987-1009. doi: 10.1124/pr.112.007252. Print 2013 Jul. Review.

18.

In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.

Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M.

AAPS J. 2013 Apr;15(2):415-26. doi: 10.1208/s12248-012-9431-9. Epub 2013 Jan 15.

19.

Determinants to optimize response to clopidogrel in acute coronary syndrome.

Giusti B, Gori AM, Marcucci R, Saracini C, Vestrini A, Abbate R.

Pharmgenomics Pers Med. 2010;3:33-50. Epub 2010 Apr 8.

20.

Risk assessment of mechanism-based inactivation in drug-drug interactions.

Fujioka Y, Kunze KL, Isoherranen N.

Drug Metab Dispos. 2012 Sep;40(9):1653-7. doi: 10.1124/dmd.112.046649. Epub 2012 Jun 8.

Supplemental Content

Support Center